The association of prenatal exposure to perfluorinated chemicals with maternal essential and long-chain polyunsaturated fatty acids during pregnancy and the birth weight of their offspring: The Hokkaido study

Environmental Health Perspectives

Volumn 123, Issue 10, 2015, Pages 1038-1045

  Kishi, Reiko ^a   Nakajima, Tamie ^b,c   Goudarzi, Houman ^a   Kobayashi, Sachiko ^a   Sasaki, Seiko ^d   Okada, Emiko ^d   Miyashita, Chihiro ^a   Itoh, Sachiko ^a   Araki, Atsuko ^a   Ikeno, Tamiko ^a   Iwasaki, Yusuke ^e   Nakazawa, Hiroyuki ^e  

^a HOKKAIDO UNIVERSITY   (Japan)

^b CHUBU UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e HOSHI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; PERFLUOROOCTANESULFONIC ACID; PERFLUOROOCTANOIC ACID; POLYUNSATURATED FATTY ACID; TRIACYLGLYCEROL; ALKANESULFONIC ACID; FLUOROCARBON; OCTANOIC ACID DERIVATIVE;

ADULT; ARTICLE; BIRTH WEIGHT; DISEASE ASSOCIATION; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; PREGNANCY; PRENATAL CARE; PRENATAL EXPOSURE; PRIORITY JOURNAL; QUESTIONNAIRE; SOCIOECONOMICS; TANDEM MASS SPECTROMETRY; ADOLESCENT; BLOOD; CHEMICALLY INDUCED; COHORT ANALYSIS; DRUG EFFECTS; EPIDEMIOLOGY; JAPAN; MALE; MATERNAL EXPOSURE; NEWBORN; YOUNG ADULT;

ADOLESCENT; ADULT; ALKANESULFONIC ACIDS; BIRTH WEIGHT; CAPRYLATES; COHORT STUDIES; FATTY ACIDS; FEMALE; FLUOROCARBONS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; INFANT, NEWBORN; JAPAN; MALE; MATERNAL EXPOSURE; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; TRIGLYCERIDES; YOUNG ADULT;

EID: 84936961319     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.1408834     Document Type: Article

References (46)

1. Abbott BD, Wolf CJ, Schmid JE, Das KP, Zehr RD, Helfant L, et al. 2007. Perfluorooctanoic acid induced developmental toxicity in the mouse is dependent on expression of peroxisome proliferator activated receptor-alpha. Toxicol Sci 98:571-581.
2. Alvarez JJ, Montelongo A, Iglesias A, Lasunción MA, Herrera E. 1996. Longitudinal study on lipoprotein profile, high density lipoprotein subclass, and postheparin lipases during gestation in women. J Lipid Res 37:299-308.
3. Apelberg BJ, Witter FR, Herbstman JB, Calafat AM, Halden RU, Needham LL, et al. 2007. Cord serum concentrations of perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) in relation to weight and size at birth. Environ Health Perspect 115:1670-1676; doi:10.1289/ehp.10334.
4. Barry V, Darrow LA, Klein M, Winquist A, Steenland K. 2014. Early life perfluorooctanoic acid (PFOA) exposure and overweight and obesity risk in adulthood in a community with elevated exposure. Environ Res 132:62-69.
5. Château-Degat ML, Pereg D, Dallaire R, Ayotte P, Dery S, Dewailly É. 2010. Effects of perfluorooctanesulfonate exposure on plasma lipid levels in the Inuit population of Nunavik (Northern Quebec). Environ Res 110:710-717.
6. Curran I, Hierlihy SL, Liston V, Pantazopoulos P, Nunnikhoven A, Tittlemier S, et al. 2008. Altered fatty acid homeostasis and related toxicologic sequelae in rats exposed to dietary potassium perfluorooctanesulfonate (PFOS). J Toxicol Environ Health A 71:1526-1541.
7. Fei C, McLaughlin JK, Tarone RE, Olsen J. 2007. Perfluorinated chemicals and fetal growth: a study within the Danish National Birth Cohort. Environ Health Perspect 115:1677-1682; doi:10.1289/ehp.10506.
8. Fisher M, Arbuckle TE, Wade M, Haines DA. 2013. Do perfluoroalkyl substances affect metabolic function and plasma lipids?-analysis of the 2007-2009, Canadian Health Measures Survey (CHMS) Cycle 1. Environ Res 121:95-103.
9. Folch J, Lees M, Sloane Stanley GH. 1957. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226:497-509.
10. Frisbee SJ, Shankar A, Knox SS, Steenland K, Savitz DA, Fletcher T, et al. 2010. Perfluorooctanoic acid, perfluorooctanesulfonate, and serum lipids in children and adolescents: results from the C8 Health Project. Arch Pediatr Adolesc Med 164:860-869.
11. Grandjean P, Bjerve KS, Weihe P, Steuerwald U. 2001. Birthweight in a fishing community: significance of essential fatty acids and marine food contaminants. Int J Epidemiol 30:1272-1278.
12. Halldorsson TI, Rytter D, Haug LS, Bech BH, Danielsen I, Becher G, et al. 2012. Prenatal exposure to perfluorooctanoate and risk of overweight at 20 years of age: a prospective cohort study. Environ Health Perspect 120:668-673; doi:10.1289/ehp.1104034.
13. Herrera E, Ortega-Senovilla H. 2010. Disturbances in lipid metabolism in diabetic pregnancy-are these the cause of the problem? Best Pract Res Clin Endocrinol Metab 24:515-525.
14. Hu W, Jones PD, Celius T, Giesy JP. 2005. Identification of genes responsive to PFOS using gene expression profiling. Environ Toxicol Pharmacol 19:57-70.
15. Innis SM. 2011. Metabolic programming of long-term outcomes due to fatty acid nutrition in early life. Matern Child Nutr 2(suppl 2):112-123.
16. Inoue K, Okada F, Ito R, Kato S, Sasaki S, Nakajima S, et al. 2004. Perfluorooctane sulfonate (PFOS) and related perfluorinated compounds in human maternal and cord blood samples: assessment of PFOS exposure in a susceptible population during pregnancy. Environ Health Perspect 112:1204-1207; doi:10.1289/ehp.6864.
17. Javins B, Hobbs G, Ducatman AM, Pilkerton C, Tacker D, Knox SS. 2013. Circulating maternal perfluoroalkyl substances during pregnancy in the C8 Health Study. Environ Sci Technol 47:1606-1613.
18. Jiang W, Zhang Y, Zhu L, Deng J. 2014. Serum levels of perfluoroalkyl acids (PFAAs) with isomer analysis and their associations with medical parameters in Chinese pregnant women. Environ Int 64:40-47.
19. Kishi R, Kobayashi S, Ikeno T, Araki A, Miyashita C, Itoh S, et al. 2013. Ten years of progress in the Hokkaido birth cohort study on environment and children's health: cohort profile-updated 2013. Environ Health Prev Med 18:429-450.
20. Kishi R, Sasaki S, Yoshioka E, Yuasa M, Sata F, Saijo Y, et al. 2011. Cohort profile: the Hokkaido study on environment and children's health in Japan. Int J Epidemiol 40:611-618.
21. Kitajima M, Oka S, Yasuhi I, Fukuda M, Rii Y, Ishimaru T. 2001. Maternal serum triglyceride at 24-32 weeks' gestation and newborn weight in nondiabetic women with positive diabetic screens. Obstet Gynecol 97(5 pt 1):776-780.
22. Konishi K, Sasaki S, Kato S, Ban S, Washino N, Kajiwara J, et al. 2009. Prenatal exposure to PCDDs/PCDFs and dioxin-like PCBs in relation to birth weight. Environ Res 109:906-913.
23. Langsted A, Freiberg JJ, Nordestgaard BG. 2008. Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation 118:2047-2056.
24. Lau C, Anitole K, Hodes C, Lai D, Pfahles-Hutchens A, Seed J. 2007. Perfluoroalkyl acids: a review of monitoring and toxicological findings. Toxicol Sci 99:366-394.
25. Lee YJ, Kim MK, Bae J, Yang JH. 2013. Concentrations of perfluoroalkyl compounds in maternal and umbilical cord sera and birth outcomes in Korea. Chemosphere 90:1603-1609.
26. Luebker DJ, Hansen KJ, Bass NM, Butenhoff JL, Seacat AM. 2002. Interactions of fluorochemicals with rat liver fatty acid-binding protein. Toxicology 176:175-185.
27. Luebker DJ, York RG, Hansen KJ, Moore JA, Butenhoff JL. 2005. Neonatal mortality from in utero exposure to perfluorooctanesulfonate (PFOS) in Sprague-Dawley rats: dose-response, and biochemical and pharamacokinetic parameters. Toxicology 215:149-169.
28. Maisonet M, Terrell ML, McGeehin MA, Christensen KY, Holmes A, Calafat AM, et al. 2012. Maternal concentrations of polyfluoroalkyl compounds during pregnancy and fetal and postnatal growth in British girls. Environ Health Perspect 120:1432-1437; doi:10.1289/ehp.1003096.
29. Monroy R, Morrison K, Teo K, Atkinson S, Kubwabo C, Stewart B, et al. 2008. Serum levels of perfluoroalkyl compounds in human maternal and umbilical cord blood samples. Environ Res 108:56-62.
30. Nakashima R, Hayashi Y, Md K, Jia X, Wang D, Naito H, et al. 2013. Exposure to DEHP decreased four fatty acid levels in plasma of prepartum mice. Toxicology 309:52-60.
31. Nakata A, Saito K, Iwasaki Y, Ito R, Kishi R, Nakazawa H. 2009. Determination of perfluorinated compounds in human milk and evaluation of their transition from maternal plasma [in Japanese]. Bunseki Kagaku 58:653-659.
32. Okada E, Kashino I, Matsuura H, Sasaki S, Miyashita C, Yamamoto J, et al. 2013. Temporal trends of perfluoroalkyl acids in plasma samples of pregnant women in Hokkaido, Japan, 2003-2011. Environ Int 60:89-96.
33. Olsen GW, Burris JM, Ehresman DJ, Froehlich JW, Seacat AM, Butenhoff JL, et al. 2007. Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluoro octanoate in retired fluorochemical production workers. Environ Health Perspect 115:1298-1305; doi:10.1289/ehp.10009.
34. Sakr CJ, Kreckmann KH, Green JW, Gillies PJ, Reynolds JL, Leonard RC. 2007. Cross-sectional study of lipids and liver enzymes related to a serum biomarker of exposure (ammonium perfluorooctanoate or APFO) as part of a general health survey in a cohort of occupationally exposed workers. J Occup Environ Med 49:1086-1096.
35. Schaefer-Graf UM, Meitzner K, Ortega-Senovilla H, Graf K, Vetter K, Abou-Dakn M, et al. 2011. Differences in the implications of maternal lipids on fetal metabolism and growth between gestational diabetes mellitus and control pregnancies. Diabet Med 28:1053-1059.
36. Seacat AM, Thomford PJ, Hansen KJ, Clemen LA, Eldridge SR, Elcombe CR, et al. 2003. Sub-chronic dietary toxicity of potassium perfluorooctanesulfonate in rats. Toxicology 183:117-131.
37. Seacat AM, Thomford PJ, Hansen KJ, Olsen GW, Case MT, Butenhoff JL. 2002. Subchronic toxicity studies on perfluorooctanesulfonate potassium salt in cynomolgus monkeys. Toxicol Sci 68:249-264.
38. Starling AP, Engel SM, Whitworth KW, Richardson DB, Stuebe AM, Daniels JL, et al. 2014. Perfluoroalkyl substances and lipid concentrations in plasma during pregnancy among women in the Norwegian Mother and Child Cohort Study. Environ Int 62:104-112.
39. Steenland K, Tinker S, Frisbee S, Ducatman A, Vaccarino V. 2009. Association of perfluorooctanoic acid and perfluorooctane sulfonate with serum lipids among adults living near a chemical plant. Am J Epidemiol 170:1268-1278.
40. Stein CR, Wolff MS, Calafat AM, Kato K, Engel SM. 2012. Comparison of polyfluoroalkyl compound concentrations in maternal serum and amniotic fluid: a pilot study. Reprod Toxicol 34:312-316.
41. Takacs ML, Abbott BD. 2007. Activation of mouse and human peroxisome proliferator-activated receptors (α, β/δ, γ) by perfluoro octanoic acid and perfluorooctane sulfonate. Toxicol Sci 95:108-117.
42. Thibodeaux JR, Hanson RG, Rogers JM, Grey BE, Barbee BD, Richards JH, et al. 2003. Exposure to perfluorooctane sulfonate during pregnancy in rat and mouse. I: maternal and prenatal evaluations. Toxicol Sci 74:369-381.
43. United Nations Environment Programme. 2007. POPRC3: Development of Risk Management Evaluation. UNEP/POPS/POPRC.3/20. Available: http://chm. pops.int/Portals/0/Repository/poprc3/UNEP-POPSPOPRC.3-POPRC-3-5.English.PDF [accessed 8 March 2013].
44. Vanden Heuvel JP, Thompson JT, Frame SR, Gillies PJ. 2006. Differential activation of nuclear receptors by perfluorinated fatty acid analogs and natural fatty acids: a comparison of human, mouse, and rat peroxisome proliferator-activated receptor-α, -β, and -γ. liver X receptor-β, and retinoid X receptor-α. Toxicol Sci 92:476-489.
45. Washino N, Saijo Y, Sasaki S, Kato S, Ban S, Konishi K, et al. 2009. Correlations between prenatal exposure to perfluorinated chemicals and reduced fetal growth. Environ Health Perspect 117:660-667; doi:10.1289/ehp.11681.
46. Winquist A, Steenland K. 2014. Modeled PFOA exposure and coronary artery disease, hypertension, and high cholesterol in community and worker cohorts. Environ Health Perspect 122:1299-1305; doi:10.1289/ ehp.1307943.